| Target Validation Information | |||||
|---|---|---|---|---|---|
| Target ID | T06671 | ||||
| Target Name | Interleukin-18 | ||||
| Target Type | Clinical Trial |
||||
| Drug Potency against Target | Iboctadekin + rituximab | Drug Info | Ki = 300000 nM | [552569] | |
| Action against Disease Model | IL-18BP | Levels of IL-18 were found to correlate with ser uM ferritin values and disease severity in adult-onset Still's disease (ASD). Western blot analysis revealed that ser uM samplesfrom patients with active ASD contained an 18-kd polypeptide of IL-18, corresponding in size to the mature form. Accordingly, the samples were able to induce IFNgamma secretion from KG-1 cells, whichwas largely abolished by neutralizing anti-IL-18 antibody. | [552249] | Drug Info | |
| The Effect of Target Knockout, Knockdown or Genetic Variations | Gene deletion resulted in Eosinophilia and Airway hyperresponsiveness increase compared to wild type | [552249] | |||
| References | |||||
| Ref 552249 | Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. Arthritis Rheum. 2001 Mar;44(3):550-60. | ||||
| Ref 552569 | Recent developments of structure based beta-secretase inhibitors for Alzheimer's disease. Curr Top Med Chem. 2005;5(16):1609-22. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.